Inhibiting Enveloped Virus Release via L-Domain Disruption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiviral therapies lack effective targets for inhibiting the late-stage processes of enveloped virus budding and release from host cells, primarily due to the complexity and large number of viral proteins involved in these processes, as well as poor understanding of host cell-virus interactions.
Innovation Solution
Development of compounds that inhibit the interaction between viral L-domain motifs and cellular proteins, specifically targeting the ESCRT machinery, by disrupting the formation of associative complexes involving L-domain motifs and cellular polypeptides, thereby blocking virus budding and release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antiviral compounds target early stage viral replication processes, then antiviral efficacy is improved, but the ability to inhibit late stage virus release is insufficient
Solution Approach 1:
The patent segments the antiviral approach by identifying and targeting specific functional domains (L-domains) within viral proteins that are responsible for late-stage budding and release processes. This segmentation allows for targeted inhibition of specific viral replication stages that were previously overlooked by broad-spectrum antivirals.
Solution Approach 2:
The patent applies local quality by focusing on specific functional regions (L-domains with motifs like PPXY, PTAP, YPXL) rather than targeting entire viral proteins. This localized targeting enables selective inhibition of virus release mechanisms while potentially sparing other viral functions.
2Reliability
If antiviral drugs target virus-specific proteins, then specificity is improved, but virus mutation to escape drug effectiveness occurs
Solution Approach 1:
The patent identifies L-domains as universal functional modules used by diverse enveloped viruses (HIV-1, influenza, Ebola, SARS-CoV-2) for budding and release. By targeting this conserved functional element rather than virus-specific proteins, the approach achieves broad-spectrum activity that is less susceptible to viral mutation and escape.
Solution Approach 2:
Instead of targeting viral proteins with the hope of finding conserved regions, the patent inverts the approach by identifying conserved functional domains (L-domains) within viral proteins and targeting those. This reversal enables the development of broad-spectrum antivirals that target essential, conserved functions across multiple virus families.
3Reliability
If compounds disrupt L-domain motif interactions with cellular proteins, then virus release is inhibited, but understanding of host cell-virus interactions is required
Solution Approach 1:
The patent extracts and isolates the critical L-domain motifs from their native viral protein contexts, enabling their study and targeting as discrete functional elements. This extraction simplifies the complex host-virus interaction by focusing on the essential binding interface between viral L-domains and cellular ESCRT machinery.
Solution Approach 2:
The patent identifies cellular ESCRT proteins (TSG101, Nedd4) as intermediary molecules that mediate the interaction between viral L-domains and the host cell budding machinery. By targeting these intermediary cellular proteins, the patent provides a strategic entry point for inhibition that leverages the host's own cellular pathways.
Data Source
AI summary
A compound having an antiviral activity for inhibiting release of an enveloped virus from a cell is disclosed, including methods of inhibiting release of an enveloped virus from a cell. The antiviral activity of the compound includes inhibiting formation of an associative complex or disrupting formation of an associative complex. The associative complex comprises an L-domain motif of the enveloped virus and at least one cellular polypeptide, or fragment thereof, capable of binding the L-domain motif of the enveloped virus.